Group 1 - Company has received the IVDR CE certification for its HIV reagent, marking the successful certification of its entire series of eight preoperative chemiluminescent detection reagents, including HIV, hepatitis B, hepatitis C, and syphilis [1][2] - A total of 229 products have now obtained IVDR CE certification, which allows them to enter the EU market and regions that recognize CE certification, positively impacting the company's business promotion in these areas [1][2] Group 2 - The company announced the results of the second vesting period of its 2023 restricted stock incentive plan, with 961,500 shares set to be listed on December 3, 2025 [3][4] - The decision-making process for the stock vesting involved multiple board meetings and independent opinions, ensuring compliance with regulations [4][5][6] Group 3 - The company has completed the registration of shares for the second vesting period, with a total of 59 individuals participating in this vesting [8][10] - The total capital after the vesting will be approximately RMB 571,388,300, with the new shares accounting for about 0.17% of the total share capital, which is not expected to significantly impact the company's financial results [11] Group 4 - The company has obtained a medical device registration certificate for the anti-gp210 antibody, which is significant for diagnosing primary biliary cholangitis (PBC) [13][14] - The registration of this medical device is expected to enhance the company's product line in the fields of liver and kidney disease detection [15]